

**SIDE EFFECTS**

**EENT:** *Conjunctival hyperemia, growth of eyelashes (hypertrichosis), ocular pigment changes, ocular pruritus, xerophthalmia, visual disturbance, ocular irritation/burning, foreign body sensation, ocular pain, blepharitis, cataracts, superficial punctate keratitis*

**INTEG:** Hyperpigmentation of the periocular skin, eyelash darkening, lacrimation, photophobia, conjunctivitis, asthenopia, iritis, macular edema

**MISC:** Influenza, upper respiratory tract infections, asthenia, headache, hirsutism

**PHARMACOKINETICS**

Ophthalmic: Onset 4 hr, peak 8-12 hr; half-life 45 min

**INTERACTIONS**

**Decrease:** Intraocular pressure—latanoprost, travoprost (no longer available in the U.S.)

**Drug/Lab Test**

**Increase:** LFTs

**NURSING CONSIDERATIONS**

**Assess:**

- **Intraocular pressure:** in those with ongoing increased IOP or those using latanoprost, travoprost (no longer available in the U.S.)

**Evaluate:**

- Decreasing IOP or increased growth of eyelashes

**Teach patient/family:**

**Ophthalmic route (Lumigan):**

- To wash hands before and after use; remove contact lenses before use and reinsert 15 min after use; Lumigan contains benzalkonium chloride, which can be absorbed by soft contact lenses

- To tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch and gently close the eyes for 1-2 min; do not blink; to avoid contamination, do not touch the tip of the dropper to the eye, fingertips, or other surface

- That the solution may be used concomitantly with other topical ophthalmic drug products to lower IOP; if more than

one topical ophthalmic drug is being used, the drugs should be administered at least 5 min apart

**Topical route (Latisse):**

- To ensure the patient's face is clean and makeup is removed before using Latisse; the disposable sterile applicator is the only applicator that should be used; each applicator should be used for 1 eye only; dispose of the applicator after each use; after applying 1 drop of solution to the applicator, apply evenly along the skin of the upper eyelid margin at the base of the eyelashes; blot excess solution runoff outside the upper eyelid margin with a tissue or other absorbent eye-lash line

**RARELY USED****binimetinib**

(bih'-nee-meh'-tih-nib)

**Mektovi**

*Func. class.:* Antineoplastic

**USES:** Treatment of unresectable/metastatic melanoma (BRAF V600E or V600K mutations) with encorafenib





**CONTRAINDICATIONS:** Hypersensitivity

**DOSAGE AND ROUTES**

- **Adult: PO** 45 mg bid with encorafenib **PO** 450 mg daily until disease progression

**bisacodyl (Rx, OTC)**

(bis-a-koe'dill)

Bisac-EVAC , Bisacolax, Bisacolax, Correctol, Carter's Little Pills , Codulax , Dacodyl, Doxidan, Dulcolax, Ex-Lax Ultra, Femilax, Fleet, Soflax-Ex 

*Func. class.:* Laxative, stimulant

*Chem. class.:* Diphenylmethane